<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Several landmark studies have recently been published in nephrology </plain></SENT>
<SENT sid="1" pm="."><plain>In summary, <z:chebi fb="0" ids="168396">mycophenolate</z:chebi> mofetil is superior to <z:chebi fb="2" ids="2948">azathioprine</z:chebi> in maintaining remission and preventing relapse in <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:hpo ids='HP_0000123'>nephritis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>For patients with <z:mp ids='MP_0002056'>type I diabetes</z:mp>, long-term renal function is better preserved when optimal glycaemic control is obtained with intensive <z:mp ids='MP_0002055'>diabetes</z:mp> therapy from the <z:hpo ids='HP_0003674'>onset</z:hpo> of disease, and in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> treatment with bardexolone may increase renal function </plain></SENT>
<SENT sid="3" pm="."><plain>With respect to <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e>, the association of simvastatine and <z:chebi fb="0" ids="49040">ezetimibe</z:chebi> is effective in improving cardiovascular outcomes </plain></SENT>
<SENT sid="4" pm="."><plain>There is no need to initiate dialysis in asymptomatic patients, and daily haemodialysis seems better than three times weekly hemodialysis </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, <z:chebi fb="0" ids="28939">N-acetylcysteine</z:chebi> does not prevent contrast <z:hpo ids='HP_0000112'>nephropathy</z:hpo> </plain></SENT>
</text></document>